MP13-Resistencias a Antiretrovirales
Medicina de Precisión / IBS-MP13
The group coordinates the Spanish HIV Research Network Work Package on subtypes and resistance and contributes with several European organizations on HIV resistance (ESAR-SPREAD, Eurocord-CHAIN, EuRESIST-INTEGRATE) and hepatitis resistance (SHARED, HEPCARE). The group has been actively involved in recent research on Transmitted Drug Resistance in Spain and Europe, on genotypic investigation on HIV viral Tropism, on clinical significance of HIV low and very low-level viraemia, and on molecualr epidemiology of HIV ti guide public helath interventions. The group is actively involved in hepatitis C virus research activities, coordianting several activities in GEHEP (Spanish Viral Hepatitis Study Group of the Clinical Microbiology & Infectious diseases Spanish Society), and coordinator of HEPCRESP, the Spanish national cohort on HCV resistance to new DAAs. The group is also in the Sterring Comittee of HEPCARE (Europe) and SHARED (Global) hepatitis
Líneas de investigación
- Eliminación de hepatitis C
- Epidemiología molecular de VIH
- Microbiota e inmunomodulación
- Microbiota y enfermedad
- Microbiota y probióticos
- Resistencias a Antirretrovirales
- Resistencias en VHC
- Resistencia a antibióticos y terapia alternativa
- smRNA e infección
Redes de investigación
- RIS - Red Española de Investigación en Sida
- CIBERINFEC - Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
Palabras clave
VIH, Hepatitis C, Microbiota.
MARTA ILLESCAS LOPEZ
LUCIA CHAVES BLANCO
LUCIA PEREZ RODRIGUEZ
ANGELA ALCARAZ MARTINEZ
PALOMA MUÑOZ BAEZ
LAURA VIÑUELA GONZALEZ
RUBEN CEBRIAN CASTILLO
ANGEL CARAZO GALLEGO
Mª DOLORES MERIDA DEL CAÑO
JOSE ANTONIO SANCHEZ ALVAREZ
MARTA ALVAREZ ESTEVEZ
NATALIA CHUECA PORCUNA
ADOLFO DE SALAZAR GONZALEZ
ANA FUENTES LOPEZ
FEDERICO GARCIA GARCIA
FERNANDO GARCIA GARCIA
JOSEFA LOPEZ BUENO
Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
ANTIOXIDANTS, 2023;
FI:7; Q1
Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023;
FI:8,4; Q1
Human adipose tissue as a major reservoir of cytomegalovirus-reactive T cells
FRONTIERS IN IMMUNOLOGY, 2023;
FI:7,3; Q1
Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study
ANTIBIOTICS-BASEL, 2023;
FI:4,8; Q2
Monkeypox Virus Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023;
FI:1,5; Q4
ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
CLINICAL MICROBIOLOGY AND INFECTION, 2022;
FI:13,31; D1
In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant
TRANSBOUNDARY AND EMERGING DISEASES, 2022;
FI:4,521; D1
Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic
TRANSBOUNDARY AND EMERGING DISEASES, 2022;
FI:4,521; D1
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe
JOURNAL OF HEPATOLOGY, 2022;
FI:30,083; D1
Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV
CLINICAL MICROBIOLOGY AND INFECTION, 2022;
FI:13,31; D1
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
JOURNAL OF CLINICAL INVESTIGATION, 2021;
FI:14,808; D1
Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties.
NUTRIENTS, 2021;
FI:5,719; Q1
Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant Staphylococcus aureus.
ANTIBIOTICS-BASEL, 2021;
FI:4,639; Q2
Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;
FI:3,267; Q3
Comparison between Aptima (R) assays (Hologic) and the CoBAS (R) 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;
FI:3,267; Q3
A Multi-Omics Approach Reveals New Signatures in Obese Allergic Asthmatic Children
BIOMEDICINES, 2020;
FI:4,717; Q1
Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells
CANCERS, 2020;
FI:6,126; Q1
Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020;
FI:2,837; Q2
Bacteria associated with periodontal disease are also increased in health
MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2020;
FI:1,596; Q3
Current position of viral load versus hepatitis C core antigen testing
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2020;
FI:1,654; Q4
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
JOURNAL OF HEPATOLOGY, 2019;
FI:18,946; D1
Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;
FI:5,113; D1
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
JOURNAL OF HEPATOLOGY, 2019;
FI:18,946; D1
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy
JOURNAL OF HEPATOLOGY, 2019;
FI:18,946; D1
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;
FI:5,113; D1
Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018;
FI:5,217; D1
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 (vol 37, pg 17, 2018)
DRUG RESISTANCE UPDATES, 2018;
FI:11,63; D1
Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018;
FI:10,231; D1
Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution
BRITISH JOURNAL OF PHARMACOLOGY, 2018;
FI:6,81; D1
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
PLOS ONE, 2018;
FI:2,766; Q1
Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis – a cross-sectional study
EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2017;
FI:3,567; D1
Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition
MOLECULAR NUTRITION & FOOD RESEARCH, 2017;
FI:4,323; D1
Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)
JOURNAL OF VIRAL HEPATITIS, 2017;
FI:4,122; Q1
High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach
PLOS ONE, 2017;
FI:2,806; Q1
Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017;
FI:3,935; Q1
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)
JOURNAL OF INFECTIOUS DISEASES, 2016;
FI:6,344; D1
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI:4,919; D1
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI:4,919; D1
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI:4,919; D1
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
CLINICAL INFECTIOUS DISEASES, 2016;
FI:8,736; D1
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clin Microbiol Infect, 2015;
FI:5,768; D1
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults
Clin Microbiol Infect, 2015;
FI:5,768; D1
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;
FI:5,313; D1
Primary resistance to integrase strand-transfer inhibitors in Europe
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;
FI:5,313; D1
Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C
JOURNAL OF INFECTION, 2015;
FI:4,441; Q1
Vigilancia epidemiológica molecular de la infección por el virus de la Hepatitis Delta
Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA
Número de expediente: GEHEP-2023-AFL
Tiempo de ejecución: 01/01/2024 - 31/12/2024
IP: ANA FUENTES LOPEZ
INFLUENCIA DE LA MICROBIOTA INTESTINAL EN LA GRAVEDAD DE PANCREATITIS AGUDA (MIGPA)
Financiador: UNIVERSIDAD DE GRANADA
Número de expediente: C-CTS-311-UGR23
Tiempo de ejecución: 01/01/2024 - 31/12/2025
IP: NATALIA CHUECA PORCUNA
Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network RELECOV 2.0
Financiador: COMISION EUROPEA
Número de expediente: RELECOV 2022
Tiempo de ejecución: 01/07/2023 - 30/06/2025
IP: FEDERICO GARCIA GARCIA
Vigilancia epidemiológica de la transmisión de resistencias a antiretrovirales en España. Implementación de una estrategia de estudio de clusters de transmisión en tiempo real.
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: PI22/00882
Tiempo de ejecución: 01/01/2023 - 31/12/2025
IP: FEDERICO GARCIA GARCIA
RELECOV 2.0 – Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network
Financiador: COMISION EUROPEA
Número de expediente: RELECOV 2022
Tiempo de ejecución: 01/03/2023 - 01/07/2024
IP: FEDERICO GARCIA GARCIA
Desarrollo de un kit comercial para la secuenciación masiva de micro RNA, basado en una tecnología innovadora de sesgos reducidos (Double Tailing Trap)
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: DTS22/00151
Tiempo de ejecución: 01/01/2023 - 31/12/2025
IP: ANGEL CARAZO GALLEGO
Caracterización de la respuesta de anticuerpos a la vacuna anti-COVID-19 BNT162b2 y sus determinantes
Financiador: CONSEJERÍA DE SALUD Y FAMILIAS
Número de expediente: PI-0198-2021
Tiempo de ejecución: 10/12/2021 - 09/12/2024
IP: FEDERICO GARCIA GARCIA
Enhancing Whole Genome Sequencing (WGS) and/or ReverseTranscription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain.
Financiador: COMISION EUROPEA
Número de expediente: HERA INCUBATOR 2021
Tiempo de ejecución: 03/09/2021 - 02/10/2022
IP: FEDERICO GARCIA GARCIA
CB21/13/00088 FEDERICO GARCÍA GARCÍA ÁREA TEMÁTICA: ENFERMEDADES INFECCIOSAS
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: CB21/13/00088
Tiempo de ejecución: 01/01/2022 - 31/12/2025
IP: FEDERICO GARCIA GARCIA
Programa de Microeliminación de hepatitis C en un centro de inserción social.
Financiador: GILEAD SCIENCES EUROPE LTD
Número de expediente: GILEAD2021-FGG
Tiempo de ejecución: 02/05/2022 - 01/05/2024
IP: FEDERICO GARCIA GARCIA
Hacia la eliminación de la hepatitis C en los pacientes con Trastorno Mental Grave
Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA
Número de expediente: GEHEP-2020/FGG
Tiempo de ejecución: 31/12/2020 - 31/12/2021
IP: FEDERICO GARCIA GARCIA
Relevancia Clínica E Impacto Económico de la Correcta Asignación del Genotipo/subtipo del Virus de la Hepatitis C en la Era de Los Antivirales de Acción Directa.
Financiador: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Número de expediente: PI-0411-2014
Tiempo de ejecución: 31/07/2015 - 30/09/2017
IP: MARTA ALVAREZ ESTEVEZ
Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con antivirales de acción directa frente al virus de la hepatitis C en regímenes libres de interferón.
Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA
Número de expediente: GEHEP-004-FGG
Tiempo de ejecución: 04/07/2017 - 03/07/2018
IP: FEDERICO GARCIA GARCIA
Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con Antivirales de acción Directa frente al Virus de la Hepatitis C
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: PI15/00713
Tiempo de ejecución: 01/01/2016 - 31/12/2018
IP: FEDERICO GARCIA GARCIA
Implantación de Una Aplicación Web para la Monitorización y Caracterización A Tiempo Real de Los Clusters Con Alta Tasa de Transmisión del Vih en Andalucía Oriental
Financiador: CONSEJERÍA DE SALUD
Número de expediente: PI-0550-2017
Tiempo de ejecución: 01/01/2018 - 31/12/2020
IP: MARTA ALVAREZ ESTEVEZ
RD16/0025/0040 – RED SIDA- FEDERICO GARCÍA GARCÍA
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: RD16/0025/0040
Tiempo de ejecución: 01/01/2017 - 31/12/2021
IP: FEDERICO GARCIA GARCIA
VIGILANCIA EPIDEMIOLOGICA DE LAS RESISTENCIAS PRIMARIAS Y TRASMITIDAS A LOS ANTIRETROVIRALES EN ESPAÑA. ESTUDIO FILOGENÉTICO, FILODINAMICO Y FILOETNICO
Financiador: INSTITUTO DE SALUD CARLOS III - FEDER
Número de expediente: PI18/00819
Tiempo de ejecución: 01/01/2019 - 31/12/2021
IP: FEDERICO GARCIA GARCIA
CDC- Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study.
Financiador: FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ
Tipo de prueba: ESTUDIO POSAUTORIZACION INDEPENDIENTE
Tiempo de ejecución: 31/08/2021 - 31/08/2025
IP: FEDERICO GARCIA GARCIA
National mapping on carbapenemases in Spain. The CARBA-MAP study
Financiador: MERCK SHARP & DOHME DE ESPAÑA SA
Tipo de prueba: ESTUDIO POSAUTORIZACION COMERCIAL
Tiempo de ejecución: 15/10/2020 - 30/09/2021
IP: NATALIA CHUECA PORCUNA
Efectividad de la doxiciclina en la negativización de la replicación viral en COVID-19. Ensayo clínico aleatorizado de Fase II.
Financiador: FUNDACIÓN PÚBLICA PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL ALEJANDRO OTERO (FIBAO)
Tipo de prueba: ENSAYO CLINICO INDEPENDIENTE
Tiempo de ejecución: 04/12/2020 - 31/12/2021
IP: NATALIA CHUECA PORCUNA